Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SNX29 antisense RNA 2 (SNX29-AS2) is a **long non-coding RNA (lncRNA)** transcribed from the strand opposite to the SNX29 (Sorting Nexin 29) gene locus. It does not encode a protein and is not known to be a classical therapeutic target such as a receptor, enzyme, or transporter. While lncRNAs like SNX29-AS2 are sometimes involved in gene regulation through mechanisms such as antisense inhibition, sponging microRNAs, or modulating chromatin structure, there are currently no curated data linking SNX29-AS2 to specific biological functions, disease involvement, biomarkers, or clinically relevant drug interactions in humans[2]. Its classification is as a non-coding RNA, possibly involved in regulatory networks such as the competing endogenous RNA (ceRNA) network, but at present there is insufficient evidence to describe detailed functions or therapeutic roles. If you are seeking data on the protein-coding SNX29 gene (Sorting Nexin 29), this is distinct: SNX29 encodes a protein involved in cellular cargo transport and has been linked to reproductive traits, neurodevelopment, and certain diseases, but SNX29-AS2 refers specifically to its antisense lncRNA transcript[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SNX29 antisense RNA 2 (SNX29-AS2).